Claret2009 - Predicting phase III overall survival in colorectal cancer

  public model
Model Identifier
MODEL1708310001
Short description
Claret2009 - Predicting phase III overall survival in colorectal cancer

This model is described in the article:

Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R.
J. Clin. Oncol. 2009 Sep; 27(25): 4103-4108

Abstract:

PURPOSE: We developed a drug-disease simulation model to predict antitumor response and overall survival in phase III studies from longitudinal tumor size data in phase II trials. METHODS: We developed a longitudinal exposure-response tumor-growth inhibition (TGI) model of drug effect (and resistance) using phase II data of capecitabine (n = 34) and historical phase III data of fluorouracil (FU; n = 252) in colorectal cancer (CRC); and we developed a parametric survival model that related change in tumor size and patient characteristics to survival time using historical phase III data (n = 245). The models were validated in simulation of antitumor response and survival in an independent phase III study (n = 1,000 replicates) of capecitabine versus FU in CRC. RESULTS: The TGI model provided a good fit of longitudinal tumor size data. A lognormal distribution best described the survival time, and baseline tumor size and change in tumor size from baseline at week 7 were predictors (P < .00001). Predicted change of tumor size and survival time distributions in the phase III study for both capecitabine and FU were consistent with observed values, for example, 431 days (90% prediction interval, 362 to 514 days) versus 401 days observed for survival in the capecitabine arm. A modest survival improvement of 39 days (90% prediction interval, -21 to 110 days) versus 35 days observed was predicted for capecitabine. CONCLUSION: The modeling framework successfully predicted survival in a phase III trial on the basis of capecitabine phase II data in CRC. It is a useful tool to support end-of-phase II decisions and design of phase III studies.

To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Format
SBML (L3V1)
Related Publication
  • Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
  • Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, Fagerberg J, Bruno R
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 9/ 2009 , Volume 27 , Issue 25 , pages: 4103-4108 , PubMed ID: 19636014
  • Pharsight Corporation, Mountain View, CA, USA.
  • PURPOSE: We developed a drug-disease simulation model to predict antitumor response and overall survival in phase III studies from longitudinal tumor size data in phase II trials. METHODS: We developed a longitudinal exposure-response tumor-growth inhibition (TGI) model of drug effect (and resistance) using phase II data of capecitabine (n = 34) and historical phase III data of fluorouracil (FU; n = 252) in colorectal cancer (CRC); and we developed a parametric survival model that related change in tumor size and patient characteristics to survival time using historical phase III data (n = 245). The models were validated in simulation of antitumor response and survival in an independent phase III study (n = 1,000 replicates) of capecitabine versus FU in CRC. RESULTS: The TGI model provided a good fit of longitudinal tumor size data. A lognormal distribution best described the survival time, and baseline tumor size and change in tumor size from baseline at week 7 were predictors (P < .00001). Predicted change of tumor size and survival time distributions in the phase III study for both capecitabine and FU were consistent with observed values, for example, 431 days (90% prediction interval, 362 to 514 days) versus 401 days observed for survival in the capecitabine arm. A modest survival improvement of 39 days (90% prediction interval, -21 to 110 days) versus 35 days observed was predicted for capecitabine. CONCLUSION: The modeling framework successfully predicted survival in a phase III trial on the basis of capecitabine phase II data in CRC. It is a useful tool to support end-of-phase II decisions and design of phase III studies.
Contributors
Submitter of the first revision: Emma Fairbanks
Submitter of this revision: Emma Fairbanks
Modellers: Emma Fairbanks

Metadata information

hasProperty (1 statement)
Mathematical Modelling Ontology Ordinary differential equation model


Curation status
Non-curated


Tags

Connected external resources

SBGN view in Newt Editor

Name Description Size Actions

Model files

MODEL1708310001_url.xml SBML L3V1 representation of Claret2009 - Predicting phase III overall survival in colorectal cancer 29.33 KB Preview | Download

Additional files

MODEL1708310001-biopax2.owl Auto-generated BioPAX (Level 2) 2.60 KB Preview | Download
MODEL1708310001-biopax3.owl Auto-generated BioPAX (Level 3) 2.71 KB Preview | Download
MODEL1708310001.m Auto-generated Octave file 3.94 KB Preview | Download
MODEL1708310001.png Auto-generated Reaction graph (PNG) 4.27 KB Preview | Download
MODEL1708310001.sci Auto-generated Scilab file 380.00 Bytes Preview | Download
MODEL1708310001.svg Auto-generated Reaction graph (SVG) 845.00 Bytes Preview | Download
MODEL1708310001.vcml Auto-generated VCML file 900.00 Bytes Preview | Download
MODEL1708310001.xpp Auto-generated XPP file 2.85 KB Preview | Download
MODEL1708310001_urn.xml Auto-generated SBML file with URNs 29.32 KB Preview | Download

  • Model originally submitted by : Emma Fairbanks
  • Submitted: Aug 31, 2017 3:39:48 PM
  • Last Modified: Aug 31, 2017 4:44:36 PM
Revisions
  • Version: 2 public model Download this version
    • Submitted on: Aug 31, 2017 4:44:36 PM
    • Submitted by: Emma Fairbanks
    • With comment: Current version of Claret2009 - Predicting phase III overall survival in colorectal cancer
  • Version: 1 public model Download this version
    • Submitted on: Aug 31, 2017 3:39:48 PM
    • Submitted by: Emma Fairbanks
    • With comment: Original import of New Model

(*) You might be seeing discontinuous revisions as only public revisions are displayed here. Any private revisions unpublished model revision of this model will only be shown to the submitter and their collaborators.